Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
Sci Rep ; 14(1): 12504, 2024 May 31.
Article in English | MEDLINE | ID: mdl-38821989

ABSTRACT

To systematically analyze the damage caused by bedrock and overburden layer slope under seismic action, a set of large-scale shaking table test was designed and completed. Interpolation of the acceleration amplification coefficient, Hilbert-Huang transform and transfer function was adopted. The damage mechanisms of the bedrock and overburden layer slopes under seismic action are systematically summarized in terms of slope displacement, acceleration field, vibration amplitude, energy, vibration frequency, and damage level. The results show a significant acceleration amplification effect within the slope under seismic action and a localized amplification effect at the top and trailing edges of the slope. With an increase in the input seismic intensity, the difference in the vibration amplitude between the overburden layer and bedrock increased, low-frequency energy of the overburden layer was higher than that of the bedrock, and the vibration frequency of the overburden layer was smaller than that of the bedrock. These differences cause the interface to experience cyclic loading continuously, resulting in the damage degree of the overburden layer at the interface being larger than that of the bedrock, reduction of the shear strength, and eventual formation of landslides. The displacement in the middle of the overburden is always greater than that at the top. Therefore, under the action of an earthquake and gravity, the damage mode of the bedrock and overburden layer slope is such that the leading edge of the critical part pulls and slides at the trailing edge, and multiple tensile cracks are formed on the slope surface.

2.
Biomater Sci ; 12(3): 807, 2024 Jan 30.
Article in English | MEDLINE | ID: mdl-38205678

ABSTRACT

Correction for 'Intracellular regulation of zinc by metal-organic framework-mediated genome editing for prostate cancer therapy' by Yanan Xue et al., Biomater. Sci., 2023, https://doi.org/10.1039/d3bm00002h.

3.
Biomater Sci ; 11(23): 7556-7567, 2023 Nov 21.
Article in English | MEDLINE | ID: mdl-37458078

ABSTRACT

Normal prostate tissues generally exhibit a higher level of zinc to maintain their special "citrate-producing" metabolism, while its level dramatically decreases during prostate tumorigenesis. Despite the significant antitumor effects, the intracellular accumulation of zinc in prostate cancer cells also promotes the expression of ZNT1, which in turn results in the efflux of zinc and attenuated cytotoxicity against cancer cells. To solve the dilemma, we developed a 2-[3-(1,3-dicarboxypropyl)ureido]pentanedioic acid (DUPA)-decorated zeolitic imidazolate framework-8 (ZIF8), which is able to load plasmid DNA encoding the Cas9 editor and single-guide RNA to form Cas9@ZIF8-DUPA nanocomplexes. The intracellular delivery of Cas9@ZIF8-DUPA simultaneously increases the level of zinc and inhibits the ZNT-1 function by disrupting the SLC30A1 gene to prevent the efflux of zinc in prostate cancer cells. Due to the high affinity between DUPA and the prostate-specific membrane antigen, Cas9@ZIF8-DUPA nanocomplexes exhibit excellent prostate tumor-targeting ability. The internalization and degradation of Cas9@ZIF8-DUPA not only release free zinc and Cas9 editors, but also reduce zinc efflux through Cas9-mediated genome editing that disables the function of ZNT1. As a result, Cas9@ZIF8-DUPA nanocomplexes exhibit significant antitumor activity and extended survival in the mouse model bearing prostate tumors. The current platform offers an alternative therapeutic strategy and holds tremendous translational potential as an anticancer nanomedicine for prostate cancer treatment.


Subject(s)
Metal-Organic Frameworks , Prostatic Neoplasms , Humans , Male , Mice , Animals , Prostate/pathology , Gene Editing/methods , Zinc , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/genetics
4.
Radiother Oncol ; 181: 109505, 2023 04.
Article in English | MEDLINE | ID: mdl-36764460

ABSTRACT

BACKGROUND: This clinical trial aims at investigate the feasibility of CTV-omitted, positron-emission tomography computed tomography (PET-CT) combined with intensity-modulated radiation therapy (IMRT) for unresectable stage III NSCLC. METHODS AND MATERIALS: This was a single-center, phase II clinical trial initiated in July 2016. Patients with unresectable stage III NSCLC undergoing routine IMRT were randomly enrolled into the study group (CTV-omitted under PET-CT guidance) and the control group (CTV-delineated). Patients received platinum-based dual-drug concurrent chemoradio therapy. In the study group, the PGTV dose was 60 Gy given in 30 daily 2 Gy fractions; in the control group, the PCTV dose was 54 Gy given in 30 daily 1.8 Gy fractions, and the PGTV dose was 60 Gy given in 30 daily 2 Gy fractions. The primary endpoint was the incidence of radiation respiratory events or esophagitis with grade 3 or higher. The secondary endpoints included objective response rate (ORR), locate control rate, progression-free survival (PFS), failure pattern and overall survival (OS). RESULTS: A total of 90 patients were enrolled between July 2016 and March 2019. The incidence of radiation respiratory events or esophagitis with grade 3 or higher was 11.1 % in the study group, significantly lower than the rate of 28.9 % in the control group (P = 0.035), basically due to the reduced irradiated volumes of the lungs and esophagus in the study group. The median PFS was 9.0 months versus 10.0 months (P = 0.597), and the median OS 31.0 months versus 26.0 months (P = 0.489) in the study group and the control group, respectively. The failure pattern was not significantly different between the two groups (P = 0.826). CONCLUSION: Omitting the CTV under PET-CT guidance has high feasibility to reduce severe radiation associated toxicity in IMRT for unresectable stage III NSCLC, without compromising the efficacy.


Subject(s)
Carcinoma, Non-Small-Cell Lung , Esophagitis , Lung Neoplasms , Humans , Carcinoma, Non-Small-Cell Lung/diagnostic imaging , Carcinoma, Non-Small-Cell Lung/radiotherapy , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/radiotherapy , Lung Neoplasms/drug therapy , Positron Emission Tomography Computed Tomography/methods , Feasibility Studies , Antineoplastic Combined Chemotherapy Protocols/therapeutic use
5.
Cancer Med ; 11(24): 4979-4988, 2022 12.
Article in English | MEDLINE | ID: mdl-35587712

ABSTRACT

Pancreatic cancer (PC) remains one of the most lethal human malignancies worldwide. Due to the insidious onset and the rapid progression, most patients with PC are diagnosed at an advanced stage rendering them inoperable. Despite the development of multiple promising chemotherapeutic agents as recommended first-line treatment for PC, the therapeutic efficacy is largely limited by unwanted drug resistance. Recent studies have identified exosomes as essential mediators of intercellular communications during the occurrence of drug resistance. Understanding the underlying molecular mechanisms and complex signaling pathways of exosome-mediated drug resistance will contribute to the improvement of the design of new oncologic therapy regimens. This review focuses on the intrinsic connections between the chemoresistance of PC cells and exosomes in the tumor microenvironment (TME).


Subject(s)
Exosomes , Pancreatic Neoplasms , Humans , Exosomes/metabolism , Drug Resistance, Neoplasm , Pancreatic Neoplasms/pathology , Tumor Microenvironment , Pancreatic Neoplasms
6.
Cancer Invest ; 40(5): 425-436, 2022 May.
Article in English | MEDLINE | ID: mdl-35225723

ABSTRACT

Radiotherapy is one of the major approaches to cancer treatment. Artificial intelligence in radiotherapy (shortly, Intelligent radiotherapy) mainly involves big data, deep learning, extended reality, digital twin, radiomics, Internet plus and Internet of Things (IoT), which establish an automatic and intelligent network platform consisting of radiotherapy preparation, target volume delineation, treatment planning, radiation delivery, quality assurance (QA) and quality control (QC), prognosis judgment and post-treatment follow-up. Intelligent radiotherapy is an interdisciplinary frontier discipline in infancy. The review aims to summary the important implements of intelligent radiotherapy in various areas and put forward the future of unmanned radiotherapy center.


Subject(s)
Artificial Intelligence , Intelligence , Humans , Prognosis
7.
Future Oncol ; 18(9): 1077-1087, 2022 Mar.
Article in English | MEDLINE | ID: mdl-34986655

ABSTRACT

Background: This study aimed to retrospectively investigate the efficacy and safety of recombinant human endostatin (Rh-endostatin) combined with radiotherapy in advanced non-small-cell lung cancer (NSCLC). Methods: Patients with unresectable stage III and IV NSCLC who treated with radiotherapy were enrolled. Patients who received Rh-endostatin infusion throughout the whole peri-radiotherapy period formed the Endostar group, and those who received no Rh-endostatin infusion were the control group. Results: The median progression-free survival was 8.0 and 4.4 months (hazard ratio: 0.53; 95% CI: 0.32-0.90; p = 0.019) and median overall survival was 40.0 and 13.1 months (hazard ratio: 0.53; 95% CI: 0.28-0.98; p = 0.045) for the Endostar and control groups, respectively. The Endostar group exhibited a numerically lower rate of radiation pneumonitis relapse, radiation pneumonitis death and pulmonary fibrosis. Conclusion: Rh-endostatin infusion throughout the peri-radiotherapy period enhanced radiosensitivity and showed better survival outcomes and a tendency toward fewer radiation-related pulmonary events in patients with NSCLC.


Recombinant human endostatin (Rh-endostatin/Endostar) combined with chemotherapy has been approved as first-line standard treatment in patients with advanced non-small-cell lung cancer (NSCLC) in China. This study aimed to retrospectively investigate the efficacy and safety of Rh-endostatin combined with radiotherapy in advanced NSCLC. Patients with unresectable stage III and IV NSCLC who treated with radiotherapy were enrolled. Patients who received Rh-endostatin infusion throughout the whole peri-radiotherapy period were the Endostar group, and those receiving no Rh-endostatin infusion were the control group. Results showed that the median progression-free survival was 8.0 and 4.4 months, and median overall survival was 40.0 and 13.1 months, for the Endostar and control groups, respectively. The Endostar group had a lower rate of radiation pneumonitis relapse, radiation pneumonitis death and pulmonary fibrosis. In conclusion, Rh-endostatin infusion throughout the peri-radiotherapy period enhanced radiosensitivity and showed better survival outcomes and a tendency toward fewer radiation-related pulmonary events in patients with NSCLC.


Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Non-Small-Cell Lung/therapy , Endostatins/therapeutic use , Lung Neoplasms/therapy , Antineoplastic Agents/adverse effects , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Non-Small-Cell Lung/secondary , Chemoradiotherapy , China , Endostatins/adverse effects , Female , Humans , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Male , Middle Aged , Neoplasm Metastasis , Progression-Free Survival , Retrospective Studies
8.
J Cancer Res Clin Oncol ; 146(8): 1941-1951, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32447486

ABSTRACT

PURPOSE: Currently, the routine screening program has insufficient capacity for the early diagnosis of lung cancer. Therefore, a type of chitosan-molecular beacon (CS-MB) probe was developed to recognize the miR-155-5p and image the lung cancer cells for the early diagnosis. METHODS: Based on the molecular beacon (MB) technology and nanotechnology, the CS-MB probe was synthesized self-assembly. There are four types of cells-three kinds of animal models and one type of histopathological sections of human lung cancer were utilized as models, including A549, SPC-A1, H446 lung cancer cells, tumor-initiating cells (TICs), subcutaneous and lung xenografts mice, and lox-stop-lox(LSL) K-ras G12D transgenic mice. The transgenic mice dynamically displayed the process from normal lung tissues to atypical hyperplasia, adenoma, carcinoma in situ, and adenocarcinoma. The different miR-155-5p expression levels in these cells and models were measured by quantitative real-time polymerase chain reaction (qRT-PCR). The CS-MB probe was used to recognize the miR-155-5p and image the lung cancer cells by confocal microscopy in vitro and by living imaging system in vivo. RESULTS: The CS-MB probe could be used to recognize the miR-155-5p and image the lung cancer cells significantly in these cells and models. The fluorescence intensity trends detected by the CS-MB probe were similar to the expression levels trends of miR-155 tested by qRT-PCR. Moreover, the fluorescence intensity showed an increasing trend with the tumor progression in the transgenic mice model, and the occurrence and development of lung cancer were dynamically monitored by the differen fluorescence intensity. In addition, the miR-155-5p in human lung cancer tissues could be detected by the miR-155-5p MB. CONCLUSION: Both in vivo and in vitro experiments demonstrated that the CS-MB probe could be utilized to recognize the miR-155-5p and image the lung cancer cells. It provided a novel experimental and theoretical basis for the early diagnosis of the disease. Also, the histopathological sections of human lung cancer research laid the foundation for subsequent preclinical studies. In addition, different MBs could be designed to detect other miRNAs for the early diagnosis of other tumors.


Subject(s)
Lung Neoplasms/diagnostic imaging , Lung Neoplasms/genetics , MicroRNAs/analysis , A549 Cells , Animals , Chitosan/chemistry , Early Detection of Cancer/methods , Heterografts , Humans , Mice , Mice, Nude , Mice, Transgenic , MicroRNAs/biosynthesis , MicroRNAs/genetics , Molecular Imaging/methods , Molecular Probes/chemistry , Nanotechnology
9.
Cancer Med ; 9(10): 3437-3444, 2020 05.
Article in English | MEDLINE | ID: mdl-32207253

ABSTRACT

There were no ideal markers to predict the development of radiation pneumonitis (RP). We want to investigate the value of variations of lymphocytes and T lymphocyte subsets in predicting RP after radiotherapy (RT) of lung cancer based on previous clinical findings. A total of 182 lung cancer patients who received RT were retrospectively analyzed. Circulating lymphocytes and T lymphocyte subsets were measured before, during, and after RT. Patients were evaluated from the start of RT to 6 months post-RT. A mice model with acute radiation-induced lung injury was established and circulating lymphocytes were measured weekly until 8 weeks after irradiation. Univariate and multivariate analyses were adopted to identify risk factors of RP. Lymphocyte levels significantly decreased (P < .001) in patients before RP symptoms developed that also was able to be seen in the mice model and the values recovered during remission of symptoms. The decrease in lymphocyte count reflected the severity of RP. Meanwhile, CD4+  T lymphocyte count was significantly lower during the occurrence of symptoms in patients with RP than in those without RP (P < .001), and it improved along with RP recovery. Levels of lymphocytes and CD4+  T lymphocyte subsets proved as independent predictors of RP. Here we showed that lower peripheral blood levels of lymphocytes and CD4+  T lymphocyte were associated with an increased risk of RP, which was validated by this mice model, and thus are associated with differences in radiation-induced lung toxicity among individuals and help identify those who are susceptible to developing RP after RT.


Subject(s)
Adenocarcinoma of Lung/radiotherapy , Carcinoma, Squamous Cell/radiotherapy , Lung Neoplasms/radiotherapy , Lung/radiation effects , Radiation Pneumonitis/blood , Radiotherapy, Intensity-Modulated/adverse effects , Small Cell Lung Carcinoma/radiotherapy , T-Lymphocyte Subsets , T-Lymphocytes , Adenocarcinoma of Lung/pathology , Adult , Aged , Aged, 80 and over , Animals , CD4 Lymphocyte Count , Carcinoma, Squamous Cell/pathology , Female , Humans , Leukocyte Count , Lung Neoplasms/pathology , Lymphocyte Count , Male , Mice , Middle Aged , Neutrophils , Retrospective Studies , Small Cell Lung Carcinoma/pathology
10.
Opt Express ; 27(22): 31362, 2019 Oct 28.
Article in English | MEDLINE | ID: mdl-31684370

ABSTRACT

An erratum is presented to correct the wrong picture in our paper.

11.
Opt Express ; 27(13): 18273-18281, 2019 Jun 24.
Article in English | MEDLINE | ID: mdl-31252773

ABSTRACT

We demonstrate a continuous-wave 2.1-µm laser with a new Ho:GdTaO4 crystal pumped by a 1940.3-nm Tm fiber laser at room temperature. The maximum output power of 11.2 W at 2068.39 nm was achieved, corresponding to a slope efficiency of 72.9%. Moreover, the beam quality factor was measured to be about 1.4 at the maximum output level.

12.
Radiat Oncol ; 14(1): 104, 2019 Jun 13.
Article in English | MEDLINE | ID: mdl-31196126

ABSTRACT

PURPOSE: Despite recent advances in multimodal treatments, the prognosis of patients with glioblastoma multiforme (GBM) remains poor. The aim of this study was to evaluate the efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with temozolomide (TMZ) for the postoperative treatment of GBM. MATERIALS AND METHODS: From February 2012 to February 2018, 80 patients with newly diagnosed and histologically confirmed GBM in our institute were reviewed retrospectively. All patients underwent complete resection or partial resection surgery and then received hypofractionated SIB-IMRT with concomitant TMZ followed by adjuvant TMZ. A total dose of 64 Gy over 27 fractions was delivered to the gross tumor volume (GTV), clinical target volume 1 (CTV1) received 60 Gy over 27 fractions, and CTV2 received 54 Gy over 27 fractions. The progression-free survival (PFS) and overall survival (OS) rates and the toxicities were evaluated. Prognostic factors were analyzed using univariate and multivariate Cox models. RESULTS: The median follow-up was 16 months (range, 5~72 months). The median PFS was 15 months, and the 1-, 2-, and 3-year PFS rates were 56.0, 27.6, and 19.5%, respectively. The median OS was 21 months, and the 1-, 2-, 3-, and 5-year OS rates were 77.6, 41.6, 32.8, and 13.4%, respectively. The toxicities were mild and acceptable. Age, KPS scores and the total number of TMZ cycles were significant factors influencing patient survival. CONCLUSION: Moderately hypofractionated SIB-IMRT combined with TMZ is a feasible and safe treatment option with mild toxicity and good PFS and OS.


Subject(s)
Brain Neoplasms/therapy , Chemoradiotherapy/methods , Glioblastoma/therapy , Postoperative Care , Radiotherapy, Intensity-Modulated/methods , Temozolomide/therapeutic use , Adult , Aged , Antineoplastic Agents, Alkylating/therapeutic use , Brain Neoplasms/pathology , Female , Glioblastoma/pathology , Humans , Male , Middle Aged , Prognosis , Radiation Dose Hypofractionation , Radiotherapy Dosage , Radiotherapy Planning, Computer-Assisted/methods , Retrospective Studies , Survival Rate , Young Adult
13.
Bioresour Technol ; 273: 462-467, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30469136

ABSTRACT

The investigation aimed at revealing the influence of an external disturbance on the rapid reformation of larger aerobic granular sludge (AGS) in an internal-circulation membrane bioreactor (IC-MBR) after long-term operation. The used IC-MBR was continuously operated well for more than one year, in which, the biomass was still in the state of AGS with a balanced average size at around 200 µm and an even size distribution. By providing short-time aeration to the biomass within this bioreactor, the characteristics of biomass were totally changed in a very short time, including the surface hydrophilicity, physic-chemical properties, and the structure of microbial community, which created suitable conditions for the growth of filamentous bacteria (Saccharibacteria). Such a variation was very beneficial to the reformation of larger AGS, which resulted in the average size of AGS increased to nearly 400 µm with a compact structure and clear edge in no more than one month.


Subject(s)
Sewage/microbiology , Aerobiosis , Biomass , Bioreactors/microbiology
14.
Bioresour Technol ; 263: 297-305, 2018 Sep.
Article in English | MEDLINE | ID: mdl-29753931

ABSTRACT

The present work revealed the heterogeneity of the sludge granules formed in a membrane bioreactor with enhanced internal circulation, and also contributed to better understanding of their forming mechanisms. By continuously carrying out an experiment lasting for more than 3 months with the floc sludge from a local municipal wastewater treatment plant as inoculation sludge, diverse aerobic sludge granules were found to be successfully self-cultivated within the reactor. The results of scanning electron microscopy, fluorescence microscope and high-throughput sequencing measurement indicated that the obtained diverse granules exhibited quite obvious heterogeneity in their basic physico-chemical and microbial properties, and filamentous bacteria actually acted as a main skeleton to keep the self-cultivated sludge granules stable in both their structure and morphology. Furthermore, stable and high COD and TN removal achieved, over 85% and 60%, respectively, which confirmed its usefulness in wastewater treatment.


Subject(s)
Bioreactors , Sewage , Waste Disposal, Fluid , Aerobiosis , Bacteria , Wastewater
15.
Drug Deliv ; 25(1): 1974-1983, 2018 Nov.
Article in English | MEDLINE | ID: mdl-30621480

ABSTRACT

Lung cancer is still the most common cancer globally. Early screening remains the key to improve the prognosis of patients. There is currently a lack of specific and sensitive methods for early screening of lung cancer. In recent years, studies have found that microRNA plays an important role in the occurrence and development of lung cancer and become a biological target in the early diagnosis of lung cancer. In this study, lung cancer cells, subcutaneous xenografts of lung cancer in nude mice, and Lox-Stop-lox K-ras G12D transgenic mice were used as models. The transgenic mice displayed the dynamic processes from normal lung tissue to atypical hyperplasia, adenomas, carcinoma in situ and lung adenocarcinoma. It was found that miR-155 and somatostatin receptor 2 (SSTR2) were expressed in all the disease stages of transgenic mice. Through molecular beacon (MB) technology and nanotechnology, chitosan-molecular beacon (CS-MB) nanoparticles and targeted octreotide (OCT) were conjugated and synthesized. The octreotide-conjugated chitosan-molecular beacon nanoparticles (CS-MB-OCT) can specifically bind to SSTR2 expressed by the lung cancer cells to achieve the goal of identification of lung cancer cells and imaging miR-155 in vivo and in vitro. Fluorescence imaging at different disease stages of lung cancer in Lox-Stop-lox K-ras G12D transgenic mice was performed, and could dynamically monitor the occurrence and development of lung cancer by different fluorescence intensity ranges. The current research, in turn, provides new idea, new method, and new technology for the early screening of lung cancer.


Subject(s)
Chitosan/chemistry , Drug Carriers/chemistry , Lung Neoplasms/diagnostic imaging , MicroRNAs/biosynthesis , Molecular Imaging/methods , Nanoparticles/chemistry , Octreotide/chemistry , Receptors, Somatostatin/biosynthesis , A549 Cells , Animals , Early Detection of Cancer , Flow Cytometry , Humans , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Mice, Nude , Mice, Transgenic , Microscopy, Confocal , Xenograft Model Antitumor Assays
16.
Molecules ; 19(9): 14710-22, 2014 Sep 16.
Article in English | MEDLINE | ID: mdl-25230125

ABSTRACT

Lung cancer is the major cause of cancer-related deaths worldwide, thus developing effective methods for its early diagnosis is urgently needed. In recent years, microRNAs (miRNAs, miR) have been reported to play important roles in carcinogenesis and have become potential biomarkers for cancer diagnosis and treatment. Molecular beacon (MB) technology is a universal technology to detect DNA/RNA expression in living cells. As a natural polymers, chitosan (CS) nanoparticles could be used as a carrier for safe delivery of nucleic acid. In this study, we developed a probe using nanoparticles of miR-155 MB self assembled with CS (CS-miR-155 MB) to image the expression of miR-155 in cancer cells. Hybridization assay showed that the locked nucleic acid (LAN) modified miR-155 MB could target miR-155 effectively and sensitively. The miR-155 MB self-assembly with CS nanoparticles formed stable complexes at the proper weight ratio. The CS nanoparticles showed higher fluorescence intensity and transfection efficiency than the lipid-based formulation transfection agent by confocal microscopy and flow cytometry analysis. The CS-MB complexes were found to be easily synthesized and exhibited strong enzymatic stability, efficient cellular uptake, high target selectivity and biocompatibility. The CS-MB complexes can also be applied in other cancers just by simply changing for a targeted miRNA highly expressed in those cancer cells. Therefore, it is a promising vehicle used for detecting miRNA expression in living cells.


Subject(s)
Chitosan/chemistry , Lung Neoplasms/diagnosis , MicroRNAs/isolation & purification , Molecular Imaging , Cell Line, Tumor , Flow Cytometry , Humans , Lung Neoplasms/genetics , MicroRNAs/biosynthesis , Microscopy, Confocal , Nanoparticles/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...